Standard Article

You have free access to this content

Therapeutic and Diagnostic Agents for Parkinson's Disease

CNS Disorders

  1. Raymond G. Booth1,
  2. John L. Neumeyer2,
  3. Ross J. Baldessarini2

Published Online: 15 SEP 2010

DOI: 10.1002/0471266949.bmc105.pub2

Burger's Medicinal Chemistry and Drug Discovery

Burger's Medicinal Chemistry and Drug Discovery

How to Cite

Booth, R. G., Neumeyer, J. L. and Baldessarini, R. J. 2010. Therapeutic and Diagnostic Agents for Parkinson's Disease. Burger's Medicinal Chemistry and Drug Discovery. 529–568.

Author Information

  1. 1

    University of Florida, Gainesville, FL

  2. 2

    Harvard Medical School, Boston, MA

Publication History

  1. Published Online: 15 SEP 2010

References

  1. References
  • 1
    Parkinson J. An Essay on the Shaking Palsy. London: Whittingham and Rowland for Sherwood, Neely and Jones; 1817.
  • 2
    Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M. Larsen JP. Epidemiology of Parkinson's disease. J Neurol 2008; 255 (Suppl 5): 1832.
  • 3
    Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990–2040. Neuroepidemiology 1993; 12: 219228.
  • 4
    Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 25972.
  • 5
    Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72 (21 Suppl 4): S1S136.
  • 6
    Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993; 43: 22272229.
  • 7
    Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord 2006; 21: 10021007.
  • 8
    Banack SA, Cox PA. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology 2003; 61: 387389.
  • 9
    Dickman MS. von Economo encephalitis. Arch Neurol 2001; 58: 16961698.
  • 10
    Wenning GK, Quinn NP. Parkinsonism. Multiple system atrophy. Baillieres Clin Neurol 1997; 6: 187204.
  • 11
    Carlsson A. Treatment of Parkinson's disease with l-dopa. The early discovery phase, and a comment on current problems. J Neural Transm 2002; 109: 777787.
  • 12
    Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry 1996; 3: 301325.
  • 13
    Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia: therapeutic implications. Biol Psychiatry 1999; 46: 13881395.
  • 14
    DeLong MR, Crutcher MD, Georgopoulos AP. Primate globus pallidus and subthalamic nucleus: functional organization. J Neurophysiol 1985; 53: 530543.
  • 15
    DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007; 64: 2024.
  • 16
    Parent A, Hazrati LN. Functional anatomy of the basal ganglia: the cortico-basal ganglia–thalamo–cortical loop. Brain Res Rev 1995; 20: 91127.
  • 17
    Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Brunton LL, Lazo JS, Parker KL,editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006. p 527546.
  • 18
    Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13: 244254.
  • 19
    Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000; 123 (Pt 9): 17671783.
  • 20
    Orieux G, Francois C, Féger J, Yelnik J, Vila M, Ruberg M, Agid Y, Hirsch EC. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 2000; 97: 7988.
  • 21
    Gwinn-Hardy K. Genetics of parkinsonism. Mov Disord 2002; 17: 645656.
  • 22
    Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43: 11731180.
  • 23
    Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kösel S. Ala30Pro mutation in the gene encoding_α-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106108.
  • 24
    Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 20452047.
  • 25
    Norris EH, Giasson BI, Lee VM. α-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60: 1754.
  • 26
    Liu D, Jin L, Wang H, Zhao H, Zhao C, Duan C, Lu L, Wu B, Yu S, Chan P, Li Y, Yang H. Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res 2008; 33: 14011409.
  • 27
    Gasser T, Muller-Myhsok B, Wszolek ZK, Dürr A, Vaughan JR, Bonifati V. Genetic complexity and Parkinson's disease. Science 1997; 277: 388389.
  • 28
    Scott WK, Staijich JM, Yamaoka LH, Speer MC, Vance JM, Roses AD, Pericak-Vance MA. Genetic complexity and Parkinson's disease. Deane Laboratory Parkinson Disease Research Group. Science 1997; 277: 387388.
  • 29
    Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341346.
  • 30
    Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815824.
  • 31
    Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 2004; 63: 305311.
  • 32
    Jain S, Wood NW, Healy DG. Molecular genetic pathways in Parkinson's disease: a review. Clin Sci 2005; 109: 355364.
  • 33
    Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 2007; 17: 331337.
  • 34
    McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006; 27: 530545.
  • 35
    Ciechanover A, Brundin P. The ubiquitin–proteasome system in neurodegenerative diseases. Sometimes the chicken, sometimes the egg. Neuron 2003; 40: 427446.
  • 36
    Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895899.
  • 37
    Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795803.
  • 38
    Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 11621166.
  • 39
    Park J, Lee SB, Lee S, Kim Y, Song S, Kim S. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 11571161.
  • 40
    Biskup S, Mueller JC, Sharma M, Lichtner P, Zimprich A, Berg D, Wüllner U, Illig T, Meitinger T, Gasser T. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann Neurol 2005; 58: 905908.
  • 41
    Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18: 363369.
  • 42
    Baba M, Nakajo S, Tu PH, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879884.
  • 43
    Soloway AH. Med Hypotheses Res 2009; 5: 1926.
  • 44
    Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 2008; 1780: 13621367.
  • 45
    Graham DG. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 1984; 5: 8395.
  • 46
    Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644653.
  • 47
    Boyd DR, Hamilton JTG, Sharma ND, Harrison JS, McRoberts WC, Harper DB. Isolation of a stable benzene oxide from a fungal biotransformation and evidence for an “NIH shift” of the carbomethoxy group during hydroxylation of methyl benzoates. Chem Commun 2000; 14811482.
  • 48
    Menberu D, Nguyen PV, Onan KD, LeQuesne PW. Convenient syntheses of stereoisomeric 1,2-epoxyestr-4-en-3-ones, putative intermediates in estradiol metabolism. J Org Chem 1992; 57: 20652072.
  • 49
    Soloway AH. Potential endogenous epoxides of steroid hormones: initiators of breast and other malignancies? Med Hypoth 2007; 69: 12251229.
  • 50
    Haber F, Weiss J. The catalysis of hydrogen peroxide. Naturwissenschaften 1932; 20: 948950.
  • 51
    Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC, Malherbe P, Da Prada M, Richards JG. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 1996; 70: 755774.
  • 52
    Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev 2006; 7: 295309.
  • 53
    Fowler JS, Logan J, Volkow ND, Wang GJ, MacGregor RR, Ding YS. Monoamine oxidase: radiotracer development and human studies. Methods 2002; 27: 263277.
  • 54
    Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK. MAO B elevation in mouse brain astrocytes results in Parkinson's pathology. PloS One 2008; 3: e1616.
  • 55
    Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O'Dell M, Li SW, Pan Y, Chung HD, Galvin JE. Aggregation of R-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008; 115: 193203.
  • 56
    Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003; 53(Suppl 3): S2636.
  • 57
    Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348355.
  • 58
    Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381389.
  • 59
    Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord. 1994; 9: 9297.
  • 60
    Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997; 69: 13261329.
  • 61
    Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69: 11961203.
  • 62
    Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58: 495505.
  • 63
    Shankar JC, Andersen JK. Redox imbalance in Parkinson's disease. Biochimica et Biophysica Acta 2008; 1780: 13621367.
  • 64
    Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992; 115 (Pt 2): 33342.
  • 65
    Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 14501455.
  • 66
    Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889909.
  • 67
    Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983; 95: 5780.
  • 68
    Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal 2000; 2: 44960.
  • 69
    Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, Bird ED, Riederer P, Jellinger K, Watanabe S, et al. Human brain dopamine receptors in children and aging adults. Synapse 1987; 1: 399404.
  • 70
    Riederer P, Woketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976; 38: 277301.
  • 71
    Calne DB. Parkinson's disease is not one disease. Parkinsonism Rel Disord 2000; 7: 37.
  • 72
    Drechsel DA, Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 2008; 44: 18731886.
  • 73
    Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008; 29: 322329.
  • 74
    Lockwood AH. Pesticides and parkinsonism: is there an etiological link? Curr Opin Neurol 2000; 13: 687690.
  • 75
    Gajdusek DC, Salazar AM. Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982; 32: 107126.
  • 76
    Kuhn W, Müller T, Nastos I, Poehlau D. The neuroimmune hypothesis in Parkinson's disease. Rev Neurosci 1997; 8: 2934.
  • 77
    Cotzias GC. Manganese in health and disease. Physiol Rev 1958; 38: 503532.
  • 78
    Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 1987; 14: 3641.
  • 79
    Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 2009; 30: 475483.
  • 80
    Miller GW. Paraquat: the red herring of Parkinson's disease research. Toxicol Sci 2007; 100: 12.
  • 81
    Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999; 823: 110.
  • 82
    Naylor JL, Widdowson PS, Simpson MG, Farnworth M, Ellis MK, Lock EA. Further evidence that the blood/brain barrier impedes paraquat entry into the brain. Hum Exp Toxicol 1995; 14: 587954.
  • 83
    Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 13011306.
  • 84
    Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW. Smoking and Parkinson's disease in twins. Neurology. 2002; 58: 581588.
  • 85
    Ward RL, Lallemand F, de Witte P, Dexter DT. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog Neurobiol 2008; 85: 135147.
  • 86
    Khalil AA, Davies B, Castagnoli N Jr. Isolation and characterisation of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem 2006; 14: 33923398.
  • 87
    Chapman MA. Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin–proteasome system? Med Hypotheses 2009. (Epub ahead of print).
  • 88
    Hernan MA, Takkouche B, Caamano-Isorna F, Gestal- Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276284.
  • 89
    Trevitt J, Kawa K, Jalali A, Larsen C. Differential effects of adenosine antagonists in two models of parkinsonian tremor. Pharmacol Biochem Behav 2009; 94: 2429.
  • 90
    Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003; 61 (11 Suppl 6): S107111.
  • 91
    Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics 2009; 6: 141151.
  • 92
    Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 297309.
  • 93
    Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990; 40 (Suppl 3): 1730.
  • 94
    Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983; 80: 45464550.
  • 95
    Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatric Res 1979; 1: 249254.
  • 96
    Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979980.
  • 97
    Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984; 120: 574578.
  • 98
    Peterson LA, Caldera PS, Trevor A, et al. Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Med Chem 1985; 28: 14321436.
  • 99
    Salach JI, Singer TP, Castagnoli N Jr, et al. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Comm 1984; 125: 831835.
  • 100
    Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225: 14801482.
  • 101
    Snyder SH, D'Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology 1986; 36: 250258.
  • 102
    Berry MD, Juorio AV, Paterson IA. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 1994; 42: 375391.
  • 103
    Ikemoto K, Kitahamaa K, Seif I, Maeda T, DeMaeyer E, Valatxa J-L. Monoamine oxidase B (MAOB)-containing structures in MAOA-deficient transgenic mice. Brain Res 1997; 771: 121132.
  • 104
    Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985; 82: 21732177.
  • 105
    Ramsay RR, McKeown KA, Johnson EA, Booth RG, Singer TP. Inhibition of NADH oxidation by pyridine derivatives. Biochem Biophys Res Comm 1987; 146: 5360.
  • 106
    Vyas I, Heikkila RE, Nicklas WJ. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 1986; 46: 15011507.
  • 107
    Castagnoli N Jr, Rimoldi JM, Bloomquist J, Castagnoli KP. Potential metabolic bioactivation pathways involving cyclic tertiary amines and aza-arenes. Chem Res Toxicol 1997; 10: 924940.
  • 108
    Watanabe H, Muramatsu Y, Kurosaki R, et al. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsychopharmacol 2004; 14: 93104.
  • 109
    Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005; 3: CD004898.
  • 110
    The Parkinson's Disease Study Group. Impact of tocopherol and deprenyl in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 2936.
  • 111
    The Parkinson's disease study group. Impact of tocopherol and deprenyl in DATATOP subjects requiring levodopa. Ann Neurol 1996; 39: 3745.
  • 112
    Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009; 72 (Suppl 7): S5964.
  • 113
    Rajput AH, Uitti RJ, Offord KO. Timely levodopa administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997; 3: 159165.
  • 114
    Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960; 38: 12361239.
  • 115
    Birkmayer W, Hornykiewicz O. The l-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961; 73: 787788.
  • 116
    Barbeau A. Biochemistry of Parkinson's disease. Proc 7th Int Cong Neurol 1961; 2: 925.
  • 117
    Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Eng J Med 1967; 276: 374379.
  • 118
    Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with l-dopa. N Engl J Med 1969; 280: 33745.
  • 119
    Barbeau A. l-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969; 101: 5968.
  • 120
    Nagatsu T. Biochemistry of Catecholamines: The Biochemical Method. Baltimore: University Park Press; 1973. p 289299.
  • 121
    Baldessarini RJ, Fischer JE. Substitute and alternative neurotransmitters in neuropsychiatric illness. Arch Gen Psychiatry 1977; 34: 958964.
  • 122
    Chalmers JP, Baldessarini RJ, Wurtman RJ. Effects of l-dopa on norepinephrine metabolism in the brain. Proc Natl Acad Sci USA 1971; 68: 662666.
  • 123
    Vogel WH. Determination and physiological disposition of p-methoxyphenylethylamine in the rat. Biochem Pharmacolo 1970; 19: 26632665.
  • 124
    Burkard WP, Gey KF, Pletscher A. Inhibition of decarboxylase of aromatic amino acids by 2,3,4-trihydroxybenzylhydrazine and its seryl derivative. Arch Biochem Biophys 1964; 107: 187196.
  • 125
    Matthysse S, Baldessarini RJ. S-Adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry 1972; 128: 13101312.
  • 126
    Miyawaki E, Lyons K, Pahwa R. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997; 20: 523530.
  • 127
    Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 5: 331342.
  • 128
    Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589598.
  • 129
    Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008; 25: 665682.
  • 130
    Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 20782081.
  • 131
    Baldessarini RJ, Tarazi FI, Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL,editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006. p 461500.
  • 132
    Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009; 459: 356363.
  • 133
    Milligan G. Mechanisms of multifunctional signaling by G protein-linked receptors. Trends Pharmacol Sci 1993; 14: 239244.
  • 134
    Raymond JR. Multiple mechanisms of receptor-G protein signaling specificity. Am J Physiol 1995; 269: F141158.
  • 135
    Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15: 598611.
  • 136
    Gay EA, Urban JD. Nichols DE Oxford GS, Mailman RB. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 2004; 66: 97105.
  • 137
    Moniri NH, Covington-Strachan D, Booth RG. Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. J Pharmacol Exp Ther 2004; 311: 274281.
  • 138
    Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 2002; 301: 11791189.
  • 139
    Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612627.
  • 140
    Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002; 301: 11667811.
  • 141
    Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007; 32: 6777.
  • 142
    Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007; 450: 383387.
  • 143
    Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 12111217.
  • 144
    Fu W, Shen J, Luo X, Zhu W, Cheng J, Yu K, Briggs JM, Jin G, Chen K, Jiang H. Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations. Biophys J 2007; 93: 14311441.
  • 145
    Krebs A, Edwards PC, Villa C, Li J, Schertler GF. The three dimensional structure of bovine rhodopsin determined by electron cryomicroscopy. J Biol Chem 2003; 278: 502170225.
  • 146
    Okada T, Le Trong I, Fox BA, Behnke CA, Stenkamp RE, Palczewski K. X-ray defraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. J Struct Biol 2000; 130: 7380.
  • 147
    Kobilka BK, Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 2007; 28: 397406.
  • 148
    Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 2001; 297: 12181226.
  • 149
    Baldessarini RJ, Arana GW, Kula NS, Campbell A, Harding M.In: Corsini GU, Gian LG,editors. Apomorphine and Other Dopaminomimetics, Basic Pharmacology. Vol. I. New York: Raven Press; 1981. p 219228.
  • 150
    Neumeyer JL, Baldessarini RJ. Apomorphine: new uses for and old drug. Pharmaceutical News 1997; 4: 1216.
  • 151
    Giesecke J. The absolute configuration of apomorphine. Acta Crystol 1977; B33: 302303.
  • 152
    Neumeyer JL, McCarthy M, Battista S, et al. Aporphines 9. The synthesis and pharmacological evaluations of (±)-9,10-dihyroxyaporphine, ([±]-isoapomorphine), (±)-, (–)-, and (+)-1,2-dihydroxyaporphine, and (+)-1,2,9,10-tetrahydroxyaprophine. J Med Chem 1973; 16: 1228.
  • 153
    Westerink BHC, Dijkstra D, Feenstra MGP, Grol CJ, Horn AS, Rollema H, Wirix E. Dopaminergic prodrugs: brain concentrations and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters. Eur J Pharmacol 1980; 61: 715.
  • 154
    Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, Akil H. Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 1992; 227: 205214.
  • 155
    Wilcox RE, Tseng T, Brusniak MY, Ginsburg B, Pearlman RS, Teeter M, DuRand C, Starr S, Neve KA. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. J Med Chem 1998; 41: 43854399.
  • 156
    Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet 1988; 1: 403406.
  • 157
    Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951; 56: 251253.
  • 158
    Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994; 17: 243259.
  • 159
    Mouradian MM, Chase TN.In: Marsden CD, Fahn S,editors. Movement Disorders. Oxford, UK: Butterworth; 1994. p 181186.
  • 160
    Stocchi F. Use of apomorphine in Parkinson's disease. Neurol Sci 2008; 29 (Suppl 5): S383386.
  • 161
    Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990; 53: 96101.
  • 162
    Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165170.
  • 163
    Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL. Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines. Neuropharmacology 1982; 21: 953961.
  • 164
    Campbell A, Kula NS, Jeppsson B, Baldessarini RJ. Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis. Eur J Pharmacol 1980; 67: 139142.
  • 165
    Campbell A, Baldessarini RJ, Gao Y, Zong R, Neumeyer JL. R(-) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: central dopaminergic behavioral activity in the rat. Neuropharmacology 1990; 29: 527536.
  • 166
    Menon MK, Clark WG, Neumeyer JL. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Eur J Pharmacol 1978; 52: 19.
  • 167
    Goddard WA 3rd, Abrol R. 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists. J Nutr 2007; 137 (6 Suppl 1): 1528S1538S.
  • 168
    Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. J Med Chem 2008; 51: 983987.
  • 169
    Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002; 303: 805814.
  • 170
    Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791804.
  • 171
    Blanchet PJ. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Can J Neurol Sci 1999; 26 (suppl 2): S2126.
  • 172
    Baldessarini RJ, Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu Rev Neurosci 1980; 3: 2341.
  • 173
    Brandstädter D, Oertel WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2002; 58: 160161.
  • 174
    Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonianian activity and tolerability of cabergoline. Neurology 1993; 43: 613616.
  • 175
    Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002; 125 (Pt 9): 20582066.
  • 176
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 14841491.
  • 177
    Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656662.
  • 178
    Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356: 69.
  • 179
    Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 28362841.
  • 180
    Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63: 12231229.
  • 181
    Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93: 37773784.
  • 182
    Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159: R11R14.
  • 183
    Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12: 153157.
  • 184
    Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 35566.
  • 185
    Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006; 29: 8086.
  • 186
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002; 287: 16531661.
  • 187
    Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebocontrolled study. Mov Disord 2001; 16: 459463.
  • 188
    Morgan JC, Sethi KD. Rotigotine for the treatment of Parkinson's disease. Expert Rev Neurother 2006; 6: 12751282.
  • 189
    LeWitt PA, Lyons KE, Pahwa R. SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007; 68: 12621267.
  • 190
    Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol 2007; 6: 513520.
  • 191
    Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272276.
  • 192
    Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16: 2345.
  • 193
    Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 2000; 15: 601603.
  • 194
    Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 1987; 68: 4150.
  • 195
    Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X. Effects of a selective partial D1 agonist, CY 208–243, in de novo patients with Parkinson disease. Mov Disord 1992; 7: 239243.
  • 196
    Neumeyer JL, Baindur N, Niznik HB, Guan HC, Seeman P. (+/−)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship. J Med Chem 1991; 34: 33663371.
  • 197
    Neumeyer JL, Kula NS, Baldessarini RJ, Baindur N. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(−) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J Med Chem 1992; 35: 14661471.
  • 198
    Kuno S. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications. Eur Neurol 1997; 38Suppl 1: 1822.
  • 199
    Grondin R, Bédard PJ, Britton DR, Shiosaki K. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997; 49: 421426.
  • 200
    Andringa G, Lubbers L, Drukarch B, Stoof JC, Cools AR. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of l-dopa and the D1 agonist SKF 82958. Behav Pharmacol 1999; 10: 175182.
  • 201
    Goulet M, Madras BK. D1 dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 2000; 292: 714724.
  • 202
    Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman RB. trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 1990; 33: 17561764.
  • 203
    Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 1989; 166: 111113.
  • 204
    Taylor JR, Lawrence MS, Redmond DE Jr, Elsworth JD, Roth RH, Nichols DE, Mailman RB. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991; 199: 389391.
  • 205
    Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 1998; 21 339343.
  • 206
    Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem 1996; 39: 285296.
  • 207
    Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem 1996; 39: 549555.
  • 208
    Asin KE, Domino EF, Nikkel A, Shiosaki K. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease. J Pharmacol Exp Ther 1997; 281: 454459.
  • 209
    Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001; 58: 249254.
  • 210
    Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 1992; 229: 203209.
  • 211
    Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, Bednarz L, Asin KE, Britton DR. Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. J Pharmacol Exp Ther 1996; 276: 10221029.
  • 212
    Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ. Nichols DE. trans-2,3-Dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem 2006; 49: 68486857.
  • 213
    Baldessarini RJ, Drug therapy of depression and anxiety disorders. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL,editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006; p. 429460.
  • 214
    Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidizes. Biochemistry 2009; 48: 42204230.
  • 215
    Glezer S, Finberg JP. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol 2003; 472: 173177.
  • 216
    Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008; 23: 2194201.
  • 217
    Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006; 67 (7 Suppl 2): S1823.
  • 218
    Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63: 746748.
  • 219
    Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24: 295299.
  • 220
    Teräväinen H, Rinne U, Gordin A. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Adv Neurol 2001; 86: 31125.
  • 221
    Lautala P, Ulmanen I, Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol Omethyltransferase. Mol Pharmacol 2001; 59: 393402.
  • 222
    Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone—a review. J Neural Transm 2004; 111: 13431363.
  • 223
    Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol 2007; 3: 28794.
  • 224
    Haasio K, Nissinen E, Sopanen L. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J Neural Transm 2002; 109: 13911401.
  • 225
    Korlipara LV, Cooper JM, Schapira AH. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone, to cultured human neuroblastoma cells. Neuropharmacology 2004; 46: 562569.
  • 226
    Tafazoli S, Spehar DD, O'Brien PJ. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 2005; 37: 311332.
  • 227
    Kurth MC, Adler CH, St. Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48: 8187.
  • 228
    Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000; 43: 43334353.
  • 229
    Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992; 14: 186195.
  • 230
    Mori A, Shindou T, Ichimura M, Nonaka H, Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996; 16: 605611.
  • 231
    Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997; 18: 338344.
  • 232
    Pinna A, di Chiara G, Wardas J, Morelli M. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996; 8: 11761181.
  • 233
    Ferré S, O'Connor WT, Fuxe K, Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 1993; 13: 54025406.
  • 234
    Kurokawa M, Koga K, Kase H, Nakamura J, Kuwana Y. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J Neurochem 1996; 66: 18821888.
  • 235
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Adenosine A2A antagonist: a novel antiparkinson's agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507513.
  • 236
    Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23: 217785.
  • 237
    Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinson's disease and complications of l-dopa therapy. Adv Neurol 1996; 69: 545550.
  • 238
    Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL,editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006. p 297315.
  • 239
    Blier P, Piñeyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann NY Acad Sci 1998; 861: 204216.
  • 240
    Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57: 18291834.
  • 241
    Christoffersen CL, Meltzer LT. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 1998; 18: 399402.
  • 242
    Bartoszyk GD, van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand: 1. Neurochemical profile. J Neural Transm 2004; 111: 113126.
  • 243
    Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O. Multicenter, open-label trial of sarizotan in Parkinson's disease patients with levodopainduced dyskinesias (SPLENDID study). Clin Neuropharmacol 2004; 27: 5862.
  • 244
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22: 179186.
  • 245
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009; 15: 445152.
  • 246
    Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006; 545: 210.
  • 247
    Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273276.
  • 248
    Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001; 22: 7576.
  • 249
    Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394397.
  • 250
    Schwab RS, Poskanzer DC, England AC Jr, Young RR. Amantadine in the treatment of Parkinson's disease. Review of more than two years' experience. JAMA 1972; 222: 792795.
  • 251
    Geldenhuys WJ, Malan SF, Bloomquist JR, Marchand AP, Van der Schyf CJ. Pharmacology and structure–activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med Res Rev 2005; 25: 2148.
  • 252
    Geldenhuys WJ, Malan SF, Bloomquist JR, Van der Schyf CJ. Structure–activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. Bioorg Med Chem 2007; 15: 15251532.
  • 253
    Le DA, Lipton SA. Potential and current use of N-Methyl-d-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001; 18: 717724.
  • 254
    Garnett ES, Firnau G, Chan PK, Sood S, Belbeck LW. [18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978; 75: 464477.
  • 255
    Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, Hitzemann R, Wolf AP. Decreased dopamine transporters with age in health human subjects. Ann Neurol 1994; 36: 237239.
  • 256
    Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, Sybirska E, al-Tikriti M, Charney DS, Malison RT. [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991; 34: 31443146.
  • 257
    Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB. N-Omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 15581561.
  • 258
    Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, Belakhlef A, Margouleff D, Yee A, Wang S, Tamagnan G, Neumeyer JL, Eidelberg D. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996; 23 (8): 9991004.
  • 259
    Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995; 278: 249252.
  • 260
    Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 11981212.
  • 261
    Martin WR, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008; 63: 388394.
  • 262
    Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208215.
  • 263
    Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm 2009. (Epub ahead of print.) PMID: 19763773.
  • 264
    Benabid AL, Chabardes S, Torres N, Piallat B, Krack P, Fraix V, Pollak P. Functional neurosurgery for movement disorders: a historical perspective. Prog. Brain Res 2009; 175: 379391.
  • 265
    Hedlund E, Perlmann T. Neuronal cell replacement in Parkinson's disease. J Intern Med 2009; 266: 358371.
  • 266
    Friling S, Andersson E, Thompson LH, Jönsson ME, Hebsgaard JB, Nanou E, Alekseenko Z, Marklund U, Kjellander S, Volakakis N, Hovatta O, El Manira A, Björklund A, Perlmann T, Ericson J. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci USA 2009; 106: 76137618.
  • 267
    Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009; 8: 4154.